https://www.selleckchem.com/products/SNS-032.html
Biologics have provided improved clinical benefits to patients, but they come at a huge expense due to the high costs associated with their development and manufacturing. Biosimilars, which have been clinically studied and have demonstrated to be efficacious and safe, are more cost-effective versions of biologics, however, their uptake has been slow in the United States (US) compared to in the European Union (EU). In this analysis, we review the challenges to increased biosimilar use in the US and the successful strategies employed to i
Like
Comment
Share
